Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of PF-08634404 alone and in combination with other anticancer therapies in advanced or metastatic renal cell carcinoma
CTR20262086Phase 2Active
- Sponsor
- Pfizer
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of PF-08634404 in renal cell carcinoma (RCC) (2 arms), sponsored by Pfizer. Primary endpoints: Confirmed objective response rate, Treatment-emergent adverse events and serious adverse events and 1 more. Started Jun 2026; status: active.
02
Drugs
PF-08634404
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20262086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262086.